Results For "Non"

1170 News Found

We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare

interviews | October 20, 2021

We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare

Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.

TB Alliance partners with Lupin for non-exclusive anti-TB drug

Policy | September 06, 2021

TB Alliance partners with Lupin for non-exclusive anti-TB drug

According to WHO, over 1.5 million people died of TB in 2020

SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants

Drug Approval | August 12, 2021

SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants

SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial

NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines

Policy | August 11, 2021

NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines

A total of 526 brands has seen a reduction of up to 90 per cent in MRP

Carbon-based non-toxic and reusable wrapper to increase shelf life of fruits

Sustainability | August 09, 2021

Carbon-based non-toxic and reusable wrapper to increase shelf life of fruits

This work has been published in the journal ‘ACS applied materials and interface’

Glenmark signs agreement with SaNOtize to manufacture NONS

News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.

Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India

Drug Approval | August 11, 2025

Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India

NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

News | August 09, 2025

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

News | August 06, 2025

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine

Sandoz to acquire Just–Evotec Biologics facility for $300 million

News | August 03, 2025

Sandoz to acquire Just–Evotec Biologics facility for $300 million

The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes

Latest Stories

Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad

Lupin launches Glucagon for Injection USP, 1mg/Vial in US

Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Dr. R. Ananthanarayanan CEO, Sajjan India

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging